Table 2 Prevalence of metabolic syndrome and metabolic score among the studied population stratified by sexual function
Variable | Total (n = 274) | NSD (n = 84) | SD (n = 190) | P value |
|---|---|---|---|---|
Prevalence of MetS | Â | Â | Â | Â |
WHO | 216(78.8%) | 64(76.2%) | 152(80.0%) | 0.4766 |
NCEP ATP III | 119(43.4%) | 35(41.7%) | 84(44.2%) | 0.6953 |
IDF | 142(51.8%) | 43(51.2%) | 99(52.1%) | 0.8889 |
Prevalence of clustering of components of MetS | Â | |||
WHO | Â | Â | Â | Â |
0 | 0(0.0%) | 0(0.0%) | 0(0.0%) | Â |
1 | 11(4.0%) | 4(4.8%) | 7(3.7%) | 0.6752 |
2 | 46(16.8%) | 16(19.0%) | 30(15.8%) | 0.5059 |
≥3 | 217(79.2%) | 64(76.2%) | 153(80.5%) | 0.4149 |
NCEP ATP III | Â | Â | Â | Â |
0 | 3(1.1%) | 0(0.0%) | 3(1.6%) | 0.2469 |
1 | 46(16.8%) | 13(15.5%) | 33(17.4%) | 0.6992 |
2 | 107(39.1%) | 34(40.5%) | 73(38.4%) | 0.7478 |
≥3 | 118(43.1%) | 32(38.1%) | 86(45.3%) | 0.2692 |
IDF | Â | Â | Â | Â |
0 | 1(0.4%) | 0(0.0%) | 1(0.5%) | 0.5053 |
1 | 20(7.2%) | 8(9.5%) | 12(6.3%) | 0.3466 |
2 | 87(31.8%) | 31(36.9%) | 56(29.5%) | 0.2231 |
≥3 | 166(60.6%) | 49(58.3%) | 117(61.6%) | 0.6122 |